According to Finsmes, the round was led by Sanofi-Genzyme BioVentures with participation from existing investors GE Ventures and B Capital Group.

The company intends to use the funds to further enhance its capabilities in large scale behavioral analytics, health outcomes measurement, and digital biomarker development using real life patient data from hundreds of applications and devices.

Led by Deborah Kilpatrick, CEO, Evidation Health combines expertise from consumer technology, data science, outcomes research, and healthcare economics to enable healthcare companies to measure product impact at scale and quantify outcomes.

Its Real Life Study Platform enables users to accelerate and enhance outcomes research through virtualized pragmatic trials at scale, quantifying the impact of digital and traditional interventions more efficiently than conventional approaches. Evidation Health works across the healthcare ecosystem with top pharmaceutical companies, payers, providers, and digital health companies.